Logo

Provides Testimony In

Board Certified Oncology, Board Certified Hematology, Leukemia, Cancer, Lymphoma, Blood Malignancy, Bone Marrow, Stem Cell, Transplants, Bone Marrow Stem Cell Transplants, Academic medicine, Medicine Professor, Multiple Myeloma, Myeloma, Hematologic Malignancies, Malignant, Unrelated Umbilical Cord Blood Allogeneic Adult Recipients Transplantation, Pediatric Recipients Transplantation,

EDUCATION

1985-1988, State University of New York at Buffalo, School of Medicine, M.D. cum laude

1983-1985, State University of New York at Buffalo Department of Physiology, Graduate research

1982-1986, State University of New York at Buffalo, M.S. Nurse Anesthesia

1978-1980, State University of New York at Buffalo, Roswell Park Division, Graduate research toward M.S. Natural Science

1972-1976, University of Rochester, B.S. Nursing

POSTGRADUATE TRAINING

1992-1994, Fellowship, Hematology/Oncology/Bone Marrow Transplantation, Roswell Park Cancer Institute, New York

1991-1992, Fellowship, Hematology/Oncology, Duke University Medical Center, North Carolina

1989-1991, Residency, Internal Medicine, Duke University Medical Center, North Carolina

1988-1989, Medical Internship, Duke University Medical Center, North Carolina

PROFESSIONAL APPOINTMENTS

2015-present   Professor of Biomedical Engineering (Adjunct).

Case Western Reserve University, Case School of Engineering

Dean:  Robert F. Kirsch, PhD

  • Responsibilities:  Principal Investigator Research and Development Laboratory.  Collaborative pre-clinical research and student advising.  Research studies:  development of monocytes from umbilical cord blood in combination with platelet rich plasma for topical therapy of chronic infected non-healing wounds; development of hematopoietic stem cells to enhance microvascular angiogenesis/neurogenesis in Parkinson’s Disease; development of T regulatory cells via NFAT1 knockdown for treatment of autoimmune diseases including type 1 diabetes; provision of ccr5 null umbilical cord blood allogeneic stem cell grafts for treatment of HIV infected patients with hematologic disorders.

 

2016-present   Senior Global Clinical Clinical Leader, Oncology, Novartis Pharmaceuticals.

  • Responsibilities: Senior Global Clinical Lead for two matrix cross-functional teams, overseeing all activities related to clinical development: first in new label indication for Ruxolitinib (JAK inhibitor; Jakavi) in GVHD in collaboration with Incyte Corp., and second Global Lead for Afuresertib (Akt inhibitor) in relapsed/refractory Multiple Myeloma. Responsible for all regulatory & clinical development documents including investigator brochure, clinical development plan (CDP), global clinical protocols, and data safety monitoring. Subject matter expert providing medical scientific input and mentorship in identifying, and evaluating novel immune-oncology products developed internally and via business development and in-licensure.  Therapeutic area Head providing scientific and clinical review and oversight of cross-functional teams responsible for immune-oncology product development.  Responsible to lead and support oncology product transition from Novartis Institute of Biomedical Research (NIBR) including clinical development, regulatory, and commercialization team members in pre-approval, submission, launch, and post-launch activities.

 

2015-16           Scientific Officer, Clinical R&D, Cell & Gene Therapy, Novartis Pharmaceuticals.

  • Responsibilities: Provide overall medical scientific leadership in idntifying, evaluating, and develolping novel cell and gene therapy products in hematology, oncology, infectious disease, regenerative, and solid organ transplantation.  Participate in periodic review of innovative cell & gene therapy technologies.  Support clinical development teams in phase I/II testing of novel technologies.  Provide clinical expertise in close alignment with regulatory agencies with focus on harmonization across regions.

 

2014-2015       Global Program Medical Director, Stem Cell Therapeutics, Novartis Pharmaceuticals.

  • Responsibilities:  Work in collaboration with Medical and Clinical Scientists, and Global Program Head to develop a portfolio of stem cell products in disease areas including hematology and organ transplantation.

 

2010-2013       Professor of Medicine and Pharmacology, Director of Stem Cell Transplantation. University of Virginia.

  • Responsibilities: Director, Stem Cell Transplant Program at University of Virginia Medical Center with responsibilities to assemble and manage faculty and staff for inpatient service, cellular processing, phereis and outpatient clinic per FACT guidelines.  Laboratory studies focused on transcription factor regulation of hematopoietic stem cells and T lymphocytes of relevance to allogeneic transplantation, and stem cell vasculogenesis in response to ischemia.  Clinical practice focused on malignant/non-malignant hematologic disorders and stem cell transplantation including unrelated umbilical cord blood allogeneic transplantation in adult hematology patients.

 

2003-2010       Associate Professor of Medicine and Pathology.  Division of Hematology / Oncology,  Case Western Reserve University /Case Comprehensive Cancer Center.

  • Responsibilities: Director, Allogeneic Transplant Program at University Hospitals of Cleveland.  Attending physician for 30 bed inpatient service and outpatient clinic.  Laboratory studies focused on cell signaling regulation of hematopoietic stem cells and T lymphocytes of relevance to allogeneic transplantation, and stem cell vasculogenesis in response to ischemia.  Clinical practice focused on unrelated umbilical cord blood allogeneic transplantation in adult hematology patients.

 

1998-2002       Assistant Professor of Medicine and Pathology.  Division of Hematology / Oncology,  Case Western Reserve University /Universtiy Hospitals of Cleveland.

  • Responsibilities: Director, Allogeneic Bone Marrow Transplant Program.  Attending physician for 30 bed inpatient service and outpatient clinic. Clinical practice focused on   unrelated umbilical cord blood allogeneic transplantation in adult and pediatric recipients.

 

1994-1998       Assistant Professor of Medicine and Pediatrics.  Division of Hematology / Oncology and Bone Marrow Transplantation, Duke University Medical Center.

  • Responsibilities: Attending physician for 15 bed inpatient service and outpatient clinic. Clinical practice focused on unrelated umbilical cord blood allogeneic transplantation.  Principal investigator in dendritic cell based immunotherapy for patients with hematologic malignancies, and immune studies in unrelated umbilical cord blood transplantation.

 

1992-1994       Clinical Research Fellow.  Divisions of Hematologic Oncology and Bone Marrow Transplantation, Roswell Park Cancer Institute, G. Herzig M.D., C. Bloomfield M.D.

  • Responsibilities:  Analyze multiparameter flow cytometry data CD34 subsets prior to autologous/allogeneic bone marrow transplantation with correlation myeloid/platelet recovery.  Research studies included evaluation of NK cell activity after dose-intensive chemotherapy.

 

1992                Clinical Research Fellow.  Pediatric Hematology – Oncology Division, Duke University Medical Center, J. Kurtzberg M.D.

  • Responsibilities:  Analyze kinetics of hematologic recovery including  CFU assays and surface marker flow cytometry post autologous bone marrow transplantation and peripheral stem cell mobilization.

 

1986-1987       Research Assistant.  Department of Medical Oncology, Roswell Park Memorial Institute, T. Han M.D., A. Islam M.D.

  • Responsibilities:  development of indirect conjugate immunoperoxidase staining of Daudi cell lines.  Also, evaluation of bone marrow reticulin/fibrosis in hairy cell leukemia.

 

1986-1987       Research Assistant.  Hematology Research Laboratory, Buffalo General Hospital, G. Logue M.D.

  • Responsibilities: analysis clinical/laboratory data  immune neutropenia.

 

1983-1985       Research Assistant.  Department of Physiology, State University of New York at Buffalo, L. Farhi M.D., S. Matalon Ph.D.

  • Responsibilities:  measurements of alveolar permeabilities in rabbit model for hyperoxia.

 

1985                Research Assistant.  Department of Medical Oncology, Roswell Park Memorial Institute, H. Ozer M.D., Ph.D.

  • Responsibilities:  incorporation of B-lym probe into E. coli PBR 322.  Use of B cell growth factor for establishment lymphoma cell lines.

AWARDS

2010                University of Virginia Cancer Center Distinguished Professorship

2010                Tenure, University of Virginia

2006                Dr. Donald and Ruth Weber Goodman Endowed Chair in Innovative Cancer Therapeutics

2005                Tenure, Case Western Reserve University, School of Medicine.

2002                Leukemia and Lymphoma Society of America, John J. Kelly Award.

1998                Leukemia and Lymphoma Society of America,  Scholar for Clinical Research.

1997                Stephen Birnbaum Translational Research Investigator of the Leukemia and Lymphoma Society of America.

1988                Alpha Omega Alpha, State University of New York at Buffalo Epsilon Chapter.

1982-1986       Dean’s List,  SUNY at Buffalo.

1976                Dean’s List, University of Rochester.

LICENSURE

  • Ohio
  • New York
  • North Carolina

BOARD CERTIFICATION

  • Diplomate, American Board of Internal Medicine, 1993.  Recertified 2003-2013. Recertified 2013-2023.
  • Board Certified, Hematology, 1994.  Recertified 2004-2014.  Recertified 2013-2024.
  • Board Eligible, Medical Oncology, 1994.

PROFESSIONAL SOCIETIES

2005-present   American Association for Advancement of Science (AAAS)

2005-present   International Society for Stem Cell Research (ISSR)

2003-present   International Society of Cellular Therapeutics (ISCT)

2002-present   American Association of Blood Banks (AABB)

2000-present   American Society of Blood and Marrow Transplantation (ASBMT)

1999-present   American Association of Immunologists (AAI)

1992-present   American Society Hematology (ASH).

2004-2013       Clinical Immunology Society

1998-2013       Eastern Cooperative Oncology Group (ECOG)

1997-present   Center for International Bone Marrow Transplant Registry (CIBMTR)

1995-2013       Graft Sources Committee:  Center for International Bone Marrow Transplant Registry

1991-present   American Society Clinical Oncologists.

1988-2013       American College of Physicians.

1988-present   Alpha Omega Alpha, SUNYAB Epsilon Chapter.

1985-2013       American Medical Association.

1996-1998       Leukemia Core Committee: Cancer and Leukemia Group B

1994-1998       Comprehensive Cancer Center, Duke University Medical Center

1994-1998       Pediatric Oncology Group

1984-1988       Society of Sigma Xi, SUNYAB Chapter.

PROFESSIONAL SERVICE ACTIVITIES

1995-1998       Leukemia Core Committee Member, Cancer and Leukemia Group B.

1996-1998       Transplant Committee Member, Cancer and Leukemia Group B..

1997-2013       Acute Leukemia Working Committee, CIBMTR.

1999-2003       Intramural Grants Review: Committee Member, Canadian Blood Services, Research and Development, Ottowa, ON.

1999-2003       Steering Committee, AIDS Malignancy Consortium.

2000-2003       Cord Blood Transplantation Study (COBLT) Steering Committee, Emmes Corporation, National Heart, Lung, Blood Institute.

2000-2003       Grants Review Committee, American Diabetes Association.

2002-2004       Hematopoietic Stem and Progenitor Biology Review Committee.  American Society of Hematology.

2002-2005       National Cancer Institute.  PDQ Database.  Protocol Reviewer.

2003                Reviewer, NHLBI Special Emphasis Panel:  ZHL1 CSR-I (S1)(S).  “Clinical Research in Peripheral Arterial Disease.”  June 12, 2003.

2003                Reviewer, NIAID Special Emphasis Panel:  ZAI1 PTM-I (J2).  “Innovative Grants on Immune Tolerance.”  November 3, 2003.

2004                Reviewer, NCI IRG Subcommittee D-Clinical Studies, NCI-D RPRB (K4).  “GVHD/Transplantation”  May 25-27, 2004.

2004-2013       Umbilical Cord Blood Banking Committee, National Marrow Donor Program.

2005                Reviewer, Cardiovascular Sciences Small Business Activities, ZRG1 CVS-K 10 B.  March 16-17, 2005.

2005                Reviewer, NHLBI Special Emphasis Panel K08 and K02 Awards, ZHL1 CSR-B (M2) (1).  April 7-8, 2005.

2005                Reviewer, NHLBI Special Emphasis Panel K08 and K02 Awards, ZHL1-HL-CSR-B 01 2.  August 11-12, 2005.

2005                Reviewer, NHLBI Special Emphasis Panel K08 and K02 Awards, ZHL1-HL-CSR-O (F1) (1).  October 31-November 1, 2005.

2005                Reviewer, NHLBI Special Emphasis Panel K01 Awards, ZHL1-HL-CSR-B (F2) (1).  November 3-4, 2005.

2005                Reviewer, NHLBI PACT (Production Assistance for Cellular Therapies). December 8, 2005.

2005                Reviewer, NHLBI Special Emphasis Panel K01 Awards, ZHL1-HL-CSR-B (F2) (1).  December 20, 2005.

2006                President Elect, International Society of Cellular Therapeutics, Berlin, May 5, 2006.

2006                Reviewer, NHLBI Special Emphasis Panel K08 and K02 Awards, ZHL1-HL-SRC(99) (F1) (1).  June 29-30, 2006.

2006                Reviewer, Center for Scientific Review Special Emphasis Panel, Council ZRG1 CVS-K 10 B, July 13, 2006.

2006-2009       Research Mentor, Dietrich Diabetes Association of Greater Cleveland.

2006                Reviewer, Center for Scientific Review Special Emphasis Panel, Council ZRG1 CVS-SRC (99) (F1)(1). Bethesda, MD, September 25-26, 2006.

2006                Reviewer, Center for Scientific Review Special Emphasis Panel, Council ZDK1 GRB-9 (J1), NIDDK November 7, 2006.

2006                Abstract Reviewer, Center for International Bone Marrow Transplantation Registry (CIBMTR) and American Society Bone Marrow Transplantation (ASBMT), BMT Tandem Meetings, Keystone, February 7, 2006.

2006-2010       Member, Accreditation Committee, Foundation for the Accreditation of Cellular Therapy (FACT).

2007                Reviewer, Center for Scientific Review, Clinical Investigator and Research Scientist Development Awards, Council ZHL1 CSR-0 (M1 S), NHLBI February 22, 2007.

2007                Committee Member, State of the Science, Cell and Gene Therapy, Center for International Bone Marrow Transplant.  February-March, 2007.

2007                Member, Advisory Committee, FDA.  Guidance for Industry:  Minimally Manipulated, Unrelated, Allogeneic Placental/Umbilical Cord Blood Intended for  Hematopoietic Reconstitution in Patients with Hematological Malignancies.”  March 30, 2007.

2007                Reviewer, Center for Scientific Review Special Emphasis Panel, Council ZHL1 CSR-X (O1) S, NHLBI Mentored Clinical Scientist Development and Independent Scientist Awards, June 12-13, 2007.

2007-2010       Member, Executive Committee (ex officio), Foundation for the Accreditation of Cellular Therapy (FACT).

2007                Reviewer, Center for Scientific Review Special Emphasis Panel, Council ZHL1 SRC (99), NHLBI Mentored Clinical Scientist Development and Independent Scientist Awards, November 1-2, 2007.

2008                Reviewer, Center for Scientific Review Special Emphasis Panel, Council ZHL1 CSR-0 (M1), NHLBI Mentored Clinical Scientist Development and Independent Scientist Awards, March 13-14, 2008.

2008-2010       Member, Transplant Quality Assurance Committee, Foundation for the Accreditation of Cellular Therapy (FACT).

2008-2010       President, International Society of Cellular Therapeutics, 2 year term, inducted Miami, May 5, 2008.

2008                Reviewer, Center for Scientific Review Special Emphasis Panel, Council ZHL1 CSR-0 (M1), NHLBI Mentored Clinical Scientist Development and Independent Scientist Awards, July 22-23, 2008.

2008                Reviewer, Center for Scientific Review Special Emphasis Panel, Council ZHL1 CSR-0 (F1) S, NHLBI Mentored Clinical Scientist Development and Independent Scientist Awards, Sept 18, 2008.

2008-2010       Member, Board of Trustees, Leukemia and Lymphoma Society.

2009                Reviewer, Center for Scientific Review Special Emphasis Panel, Council ZHL1 CSR-0 (F1) S, NHLBI Mentored Clinical Scientist Development and Independent Scientist Awards, July 16, 2009.

2009                Member, Clinical Research Training Institute, American Society of Hematology.

2009                Outside Faculty Review, Michael Verneris, MD, University of Minnesota.

2009-present   Member, Executive Committee. World Marrow Donor Association (WHO).

2010                Reviewer, European Commission FP7 Seventh Framework Programme for Research and Technological Development.  Brussels, Belgium January 15-19, 2010.

2010                Reviewer, Center for Scientific Review Special Emphasis Panel/Scientific Review Group, Council ZCA1 PCRB-A (A1) S, NCI Loan Repayment Program, May 17, 2010.

2010                Reviewer, Center for Scientific Review Special Emphasis Panel, Council ZHL1 CSR-U (O1), NHLBI Mentored Clinical Scientist Development and Independent Scientist Awards, June 17-18, 2010.

2010-2012       Chairman of the Board, International Society of Cellular Therapeutics, 2 year term, inducted Philadelphia, May 12 2010.

2010                Reviewer, National Heart, Lung, Blood Institute, Center for Scientific Review Special Emphasis Panel, Council ZCA1 CSR-U (O1), NHLBI Mentored Clinical Scientist Development and Independent Scientist Awards, October 8, 2010.

2011                Reviewer, NIAID Special Emphasis Panel Program Project Grant:  ZAI1 PTM-I (J2).  “Peripheral Mechanisms of Allorecognition and Tolerance.” January 31, 2011.

2011                Reviewer, Center for Scientific Review Special Emphasis Panel/Scientific Review Group, Council ZCA1 CSR-U (O1), NHLBI Mentored Clinical Scientist Development and Independent Scientist Awards, February 25, 2011.

2011                Reviewer, Center for Scientific Review National Institutes of Health Small Business Innovation Review Panel, Council ZRG1 VH-A (10), Bethesda, MD, March 11, 2011.

2011                Reviewer, National Cancer Institute, LRP Center for Scientific Review Special Emphasis Panel, Council ZCA1 PCRB-A (A1) B, Clinical Research: Loan Repayment Program, May 17, 2011.

2011                Reviewer, Center for Scientific Review Special Emphasis Panel/Scientific Review Group, Council ZHL1 CSR-K (O1) 1, NHLBI Mentored Clinical Investigator Award: Independent Scientist Research, June 16, 2011.

2011                Outside Faculty Review.  University of Rochester School of Medicine and Dentistry Promotion and Tenure Committee.  Jane Liesveld, MD, July 21, 2011.

2011                Reviewer, Center for Scientific Review Special Emphasis Panel/Scientific Review Group, Council ZDK1 GRB-1 (J3) 1, NIDDK/NHLBI Ischemic Tissue Therapy, November 2, 2011.

2011                Reviewer, Center for Scientific Review National Institutes of Health Small Business Hematology Innovation Review Panel, Council ZRG1 VH-F (10), Bethesda, MD, November 15-16, 2011.

2012                Reviewer, Center for Scientific Review National Institutes of Health Small Business Innovation Review Panel, Council ZRG1 VH-F (10), Bethesda, MD, March 13-14, 2012.

2012                Reviewer, Center for Scientific Review National Institutes of Health Special Emphasis Panel/Scientific Review Group, Council ZHL1 CSR-K (02), Bethesda, MD, June 21-22, 2012.

2012                Reviewer, NYSTEM Peer Review Committee, Herndon, VA, July 23-25, 2012.

2013                Reviewer, Center for Scientific Review National Institutes of Health Special Emphasis Panel/Scientific Review Group, Council ZAI1-LAR-I-M1, Bethesda, MD, February 5, 2013.

2013                Reviewer, Amy Strelzer Manasevit Scholars, National Marrow Donor Program.  Minneapolis, MN, February 5, 2013.

2013                Reviewer, Center for Scientific Review National Institutes of Health, NIAID Special Emphasis Panel/Scientific Review Group, Council ZAI1 JBS-A (S1), Clinical Trials for HIV/AIDS Networks (UM-1). June 10, 2013.

2013-present   New York Blood Center, Member, Data Safety Monitoring Board.

2013                Reviewer, NYSTEM Peer Review Committee, Herndon, VA, Oct 28, 2013.

2013                Reviewer, Center for Scientific Review National Institutes of Health, Comparative Medicine Special Emphasis Panel/Scientific Review Group “Improvement of Animal Models for Stem Cell-Based Regenerative Medicine”, Council 20114/01 ZOD1 CM-6 (01). December 10-12, 2013.

2013-present   Vice President North and South America, World Marrow Donor Association.

2013-2015       Member, Board of Directors, American Association of Blood Banks

2014                Reviewer, National Marrow Donor Program, Amy Strelzer Manasevit Research Program

2014                Reviewer, Center for Scientific Review National Institutes of Health, “Improvement of Animal Models for Stem Cell-Based Regenerative Medicine”, Special Emphasis Panel. March, 2014.

2014                Reviewer, Center for Scientific Review National Institutes of Health, National Heart Lung Blood Institute, “Basic Research in the Pathogenesis of HIV-Related Heart, Lung, and Blood (HLB) Diseases in Adults and Children”, Special Emphasis Panel. April, 2014, and August, 2014.

2014                Reviewer, Center for Scientific Review National Institutes of Health, National Institute of Allergy and Infectious Diseases, “Beyond HAART:  Innovative Approaches to Cure HIV-1 (U19)”, Special Emphasis Panel ZAI1 BP-A-J3. December 10-12, 2014.

2015                Reviewer, Center for Scientific Review National Institutes of Health, National Heart Lung Blood Institute, “Stem Cell Derived Blood Products”, Special Emphasis Panel ZHL1 CSR-B (S1). June 18-19, 2015.

2016                Reviewer, Center for Scientific Review National Institutes of Health, “Transformative Research Award Review”, Special Emphasis Panel ZRG1 BCMB-A (51)R. March 30, 2016.

2016                Reviewer, NYSTEM Oversight Panel Mount Sinai Consortium, New York, NY, Feb 3-5, 2016.

2017                Reviewer, Center for Scientific Review National Institutes of Health National Heart Lung Blood Institute, SBIR Panel Hematology ZRG1 VH-F (10) B, Bethesda, MD, March 9, 2017.

2017                Reviewer, Center for Scientific Review National Institutes of Health National Heart Lung Blood Institute, SBIR Panel Hematology ZRG1 VH-F (10) B, Bethesda, MD, July 18-19, 2017.

SERVICE ON MEDICAL SCHOOL, HOSPITAL OR UNIVERSITY COMMITTEES

1994-1997       Committee Member, Cancer Protocol Review Committee, Duke Comprehensive Cancer Center.

1998-2010       Ad Hoc Review Committee Member, CWRU/UHC Comprehensive Cancer Center Protocol Development and Review Committee.

1998-2010       Comprehensive Cancer Center, Case Western Reserve University /Universtiy Hospitals of Cleveland.  Member, Hematopoietic and Immune Cell Biology Program.

1999-2010       Internship Selection Committee, Department of Medicine, Case Western Reserve University / University Hospitals of Cleveland.

1998-2009 Member, Center for AIDS Research (CFAR), Case Western Reserve University.

2000-2001       Member, Ph.D. Dissertation Committee for Pingfu Fu, Case Western Reserve University.

2000-2010       Chair, Stem Cell Protocol Patient Review Committee.  Case Western Reserve University, University Hospitals of Cleveland.

2002-2009 Member, Clinical Trials Protocol Development and Review Committee.  Case Western Reserve University, University Hospitals of Cleveland.

2002-2008Internal Advisory Committee, Center for AIDS Research (CFAR), Case Western Reserve University.

2004-2008       Member, Ph.D. Dissertation Committee for Danielle MacKay, Case Western Reserve University, Department of Biology.

2004                Immunology Task Force, Case Western Reserve University, School of Medicine, George Stark, PhD, committee chair.

2005                Search Committee, Ohio Eminent Scholar, Case Western Reserve University, School of Medicine.  Stanton Gerson, MD, committee chair.

2005                Search Committee, Victor and Ellen Cohn Chair for Inflammatory Bowel Disease, Case Western Reserve University, School of Medicine, Claudio Fiocchi, MD, committee chair.

2005                Search Committee, Hellerstein Professor Chair, and Chief Cardiology, Case Western Reserve University, School of Medicine. Robert Salada, MD, committee chair.

2006-2010       Member, Ph.D. Dissertation Committee for R. Patrick Weitzel, Case Western Reserve University.

2006-2010       Member, Committee on Appointments, Promotions and Tenure, Department of Medicine, School of  Medicine, Case Western Reserve University.

2006                Member, Saudi Arabia Task Force, King Faisal Hospital, Department of Medicine, School of  Medicine, Case Western Reserve University.

2007-2010       Member, K08 Committee for Lan Zhou, MD, Case Western Reserve University.

2005-2007       Member, M.S. Dissertation Committee for Laura Fanning, Case Western Reserve University.

2008-2010       Member, Conflict of Interest Committee, Case Western Reserve University.

2008-2010       Member, K12 Committee, Rose Beck, MD, Case Western Reserve University.

2009-2010       Faculty for Block 5 IQ (second year students) Case Western School of Medicine. 

2011-2013       Search Committee, Cancer Center Director, University of Virginia School of Medicine. 

2011-2013       Member, Conflict of Interest Committee, University of Virginia School of Medicine.

2012                Review Committee, Chair, Cell Biology, B. Gambino, PhD., University of Virginia,  Peer ReviewSchool of Medicine.

2012-2013       Member, Executive Committee, University of Virginia Cancer Center.

PUBLICATIONS​

Approximately 90 Publications – Available Upon Request

CHAPTERS/REVIEWS

Approximately 30 Chapter/Reviews – Available Upon Request

TEXTBOOK EDITOR

Available Upon Request

Abstracts

Approximately 75 Abstracts – Available Upon Request

Manuscript Reviewer

Approximately 13 Manuscript Reviews – Available Upon Request

Invited Presentations

Approximately 40 Invited Presentations – Available Upon Request

Workshops and Symposium Organization

Available Upon Request

Letters

Available Upon Request

Clinical Trials

Approximately 30 Clinical Trials – Available upon Request

Investigational New Drug Application

Available Upon Request

Current Patent Applications (Pending)

Available Upon Request

Clinical and Laboratory Trainees

Available Upon Request

Grants

Approximately 40 Total Grants

Research or Equivalent Grants

Available Upon Request

Foundation Grants

Available Upon Request

Commercial/Pharmaceutical Grants

Available Upon Request

Speak With This Expert For Free

Request This Expert

Can’t Find The Right Expert?

Click Here & We Will Help You